Prebiotics for irritable bowel syndrome

References

• Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment. Pharmacol. Ther.17, 643–650 (2003).
   PubMed Web of Science ®Google Scholar
• Kang JY. Systematic review: the influence of geography and ethnicity in irritable bowel syndrome. Aliment. Pharmacol. Ther.21, 663–676 (2005).
   PubMed Web of Science ®Google Scholar
• Gwee KA. Irritable bowel syndrome in developing countries – a disorder of civilization or colonization? Neurogastroenterol. Motil.17, 317–324 (2005).
   PubMed Web of Science ®Google Scholar
• Simren M, Brazier J, Coremans G et al. Quality of life and illness costs in irritable bowel syndrome. Digestion69, 254–261 (2004).
   PubMed Web of Science ®Google Scholar
• Quigley EMM, Bytzer P, Jones R, Mearin F. Irritable bowel syndrome: the burden and unmet needs in Europe. Dig. Liver Dis.38, 717–723 (2006).
   PubMedGoogle Scholar
• Quigley EMM, Bergmann J-F, Bytzer P et al. An evidence-based approach to the management of irritable bowel syndrome in Europe. Eur. J. Gastroenterol. Hepatol.19(Suppl. 1), S1–S37 (2007).
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology130, 1480–1491 (2006).
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Bjorkman D, Fennerty MB et al. Systematic review on the management of irritable bowel syndrome in North America. Am. J. Gastroenterol.97(Suppl. II), S7–S26 (2002).
   PubMed Web of Science ®Google Scholar
• Mayer EA. Clinical practice. Irritable bowel syndrome. N. Engl. J. Med.358, 1692–1699 (2008).
   PubMed Web of Science ®Google Scholar
• Tillisch K, Wang Z, Kilpatrick L, Holschneider DP, Mayer EA. Studying the brain–gut axis with pharmacological imaging. Ann. NY Acad. Sci.1144, 256–264 (2008).
   PubMed Web of Science ®Google Scholar
• Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology124, 1662–1671 (2003).
   PubMed Web of Science ®Google Scholar
• De Giorgio R, Barbara G. Is irritable bowel syndrome an inflammatory disorder? Curr. Gastroenterol. Rep.10, 385–390 (2008).
   PubMedGoogle Scholar
• Dinan TG, Quigley EMM, Ahmed SMM et al. Hypothalamic–pituitary–gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology130, 304–311 (2006).
   PubMed Web of Science ®Google Scholar
• Quigley EMM. Disturbances of motility and visceral hypersensitivity in irritable bowel syndrome: biological markers or epiphenomenon. Gastroenterol. Clin. N. Am.34, 221–233 (2005).
   PubMed Web of Science ®Google Scholar
• Quigley EMM. Bacteria: a new player in gastrointestinal motility disorders – infections, bacterial overgrowth and probiotics. Gastroenterol. Clin. N. Am.36, 735–748 (2007).
   PubMed Web of Science ®Google Scholar
• Kassinen A, Krogius-Kurikka L, Mäkivuokko H et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology133, 24–33 (2007).
   PubMed Web of Science ®Google Scholar
• Codling C, O’Mahony L, Shanahan F, Quigley EM, Marchesi JR. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig. Dis. Sci. DOI: 10.1007/s10620-009-0934-x (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Dunlop SP, Jenkins D, Neal KR et al. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment. Pharmacol. Ther.18, 77–84 (2003).
   PubMed Web of Science ®Google Scholar
• Corinaldesi R, Stanghellini V, Cremon C et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof of concept study. Aliment. Pharmacol. Ther.30(3), 245–252 (2009).
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chow E, Lin H. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am. J. Gastroenterol.98, 412–419 (2003).
   PubMed Web of Science ®Google Scholar
• Pimentel M, Park S, Mirocha J et al. The effect of a nonabsorbed antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann. Intern. Med.145, 557–563 (2006).
   PubMed Web of Science ®Google Scholar
• Quigley EMM. A 51-year-old with irritable bowel syndrome: test or treat for bacterial overgrowth? Clin. Gastroenterol. Hepatol.5(10), 1140–1143 (2007).
   PubMed Web of Science ®Google Scholar
• Vanner S. The small intestinal bacterial overgrowth irritable bowel syndrome hypothesis: implications for treatment. Gut57, 1315–1321 (2008).
   PubMed Web of Science ®Google Scholar
• Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. DOI: 10.1016/j.cgh.2009.06.031 (2009) (Epub ahead of print).
   Google Scholar
• Lembo A, Zakko SF, Ferreira NL et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology134, A545 (2008).
   Google Scholar
• Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis. Colon Rectum51, 1775–1780 (2008).
   PubMed Web of Science ®Google Scholar
• McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J. Gastroenterol.14, 2650–2661 (2008).
   PubMed Web of Science ®Google Scholar
• Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol.9(1), 15 (2009).
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Ford AC, Talley NJ et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut DOI: gut.2008.167270v1 (2008) (Epub ahead of print).
   Google Scholar
• Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am. J. Gastroenterol.104(4), 1033–1049 (2009).
   PubMed Web of Science ®Google Scholar
• Kajander K, Krogius-Kurikka L, Rinttila T et al. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. Aliment. Pharmacol. Ther.26, 463–473 (2007).
   PubMed Web of Science ®Google Scholar
• Kajander K, Myllyluoma E, Rajilić-Stojanović M et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment. Pharmacol. Ther.27, 48–57 (2008).
   PubMed Web of Science ®Google Scholar
• O’Mahony L, McCarthy J, Kelly P et al. A randomized, placebo-controlled, double-blind comparison of the probiotic bacteria lactobacillus and bifidobacterium in irritable bowel syndrome (IBS): symptom responses and relationship to cytokine profiles. Gastroenterology128, 541–551 (2005).
   PubMed Web of Science ®Google Scholar
• Agrawal A, Houghton LA, Morris J et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173–010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther.29(1), 104–114 (2008).
   PubMed Web of Science ®Google Scholar
• Roberfroid M. Prebiotics: the concept revisited. J. Nutr.137(3 Suppl. 2), S830–S837 (2007).
   PubMed Web of Science ®Google Scholar
• Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut45(Suppl. 2), II43–II47 (1999).
   PubMed Web of Science ®Google Scholar
• Depeint F, Tzprtzis G, Vulevic J, L’anson K, Gibson GR. Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 44171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study. Am. J. Clin. Nutr.87, 785–791 (2008).
   PubMed Web of Science ®Google Scholar
• Vos AP, M’Rabert L, Stahl B, Boehm G, Garssen J. Immunomodulatory effects and potential working mechanisms of orally applied nondigestible carbohydrates. Crit. Rev. Immunol.27, 97–140 (2007).
   PubMed Web of Science ®Google Scholar
• Biarti B, Matterelli P. The family Bifidobacteria. In: The Prokaryotes. Dworkin M, Fallow S, Rosenberg E, Schieifer KH, Stackebrandt E (Eds). Springer, NY, USA, 1–70 (2001).
   Google Scholar
• Whorwell PJ, Altringer L, Morel J et al. Efficacy of an encapsulated probiotic Bifidobacterium Infantis 35624 in women with irritable bowel syndrome. Am. J. Gastroenterol.101, 1581–1590 (2006).
   PubMed Web of Science ®Google Scholar
• Guyonnet D, Chassany O, Ducrotte P et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment. Pharmacol. Ther.26, 475–486 (2007).
   PubMed Web of Science ®Google Scholar
• Kim HJ, Camilleri M, McKenzie S et al. A randomized controlled trail of a probiotic, VSL#3 on gut transit and symptoms in diarrhoea-predominant IBS. Aliment. Pharmacol. Ther.17, 895–904 (2003).
   PubMed Web of Science ®Google Scholar
• Kim HJ,Vazquez Roque MI, Camilleri M et al. A randomised controlled trial of probiotic combination VSL#3 and placebo in IBS with bloating: Neurogastroenterol. Motil.17, 687–696 (2005).
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Chey WD, Foxx-Orenstein AE et al. The American College of Gastroenterology Task force on IBS. An evidence-based position statement on the management of irritable bowel syndrome. Am. J. Gastroenterol.104(Suppl. 1), S1–S35 (2009).
   PubMed Web of Science ®Google Scholar
• Ford AC, Talley NJ, Spiegel BM et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. Br. Med. J.337, A2313 (2008).
   PubMed Web of Science ®Google Scholar
• Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut58, 367–378 (2009).
   PubMed Web of Science ®Google Scholar
• Pasricha PJ. Desperately seeking serotonin. A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology132, 2287–2290 (2007).
   PubMed Web of Science ®Google Scholar
• Hamilton-Miller JMT. Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microb. Ecol. Health Dis.13, 212–216 (2001).
   Google Scholar
• Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol. Motil.19, 166–172 (2007).
   PubMed Web of Science ®Google Scholar
• Sen S, Mulan MM, Parker TJ et al. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig. Dis. Sci.47, 2615–2620 (2002).
   PubMed Web of Science ®Google Scholar
• Barrett JS, Canale KE, Gearry RB, Irving PM, Gibson PR. Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. World J. Gastroenterol.14, 5020–5024 (2008).
   PubMed Web of Science ®Google Scholar
• Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, Liu CH. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther.28, 994–1002 (2008).
   PubMed Web of Science ®Google Scholar
• Bueno L, de Ponti F, Fried M et al. Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity. Neurogastroenterol. Motil.19(1 Suppl.), 89–119 (2007).
   PubMed Web of Science ®Google Scholar
• Rousseaux C, Thuru X, Gelot A et al.Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat. Med.13, 35–37 (2007).
   PubMed Web of Science ®Google Scholar
• Silk DBA, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-glucooligosaccharide on faecal microbiota and symptoms in irritable bowel syndrome. Aliment. Pharmacol. Ther.29, 508–518 (2009).
   PubMed Web of Science ®Google Scholar
• Andriulli A, Neri M, Loguercio C et al. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. J. Clin. Gastroenterol.42(Suppl. 3 Pt 2), S218–S223 (2008).
   PubMed Web of Science ®Google Scholar
• Colecchia A, Vestito A, La Rocca A, Pasqui F, Nikiforaki A, Festi D; Symbiotic Study Group. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol. Dietol.52, 349–358 (2006).
   PubMedGoogle Scholar
• Tsuchiya J, Barreto R, Okura R et al. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin. J. Dig. Dis.5, 169–174 (2004).
   PubMedGoogle Scholar
• Dughera L, Elia C, Navino M, Cisarò F; ARMONIA Study Group. Effects of symbiotic preparations on constipated irritable bowel syndrome symptoms. Acta Biomed.78, 111–116 (2007).
   PubMedGoogle Scholar
• Bouhnik Y, Neut C, Raskine L et al. Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation. Aliment. Pharmacol. Ther.19, 889–899 (2004).
   PubMed Web of Science ®Google Scholar
• Dunne C, Murphy L, Flynn S et al. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek76, 279–292 (1999).
   PubMed Web of Science ®Google Scholar